Class action lawsuit accuses AbbVie of creating ‘patent thicket’ for Humira
AbbVie is once again facing pressure for its alleged attempts to protect its blockbuster medication, Humira, from generics competition. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - March 20, 2019 Category: Pharmaceuticals Source Type: news
Cancer Drugs Dominate Top 10 Best-Selling Drugs in 2018 Cancer Drugs Dominate Top 10 Best-Selling Drugs in 2018
But Humira is the top seller in US 2 years running, while two immune checkpoint inhibitors break into the top 10.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 19, 2019 Category: Consumer Health News Tags: Family Medicine/Primary Care News Source Type: news
Medical News Today: Stelara vs. Humira: What's the difference?
Stelara and Humira are two biologics that help treat immune conditions, such as psoriatic arthritis and Crohn ’s disease. In this article, we look at the similarities and differences in their effects, benefits, and risks. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 14, 2019 Category: Consumer Health News Tags: Rheumatology Source Type: news
Entyvio Tops Humira in Head-to-Head UC trial
(MedPage Today) -- More vedolizumab patients achieved clinical remission, mucosal healing in VARSITY trial (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - March 13, 2019 Category: Primary Care Source Type: news
Alvotech Enrolls First Patient in Clinical Phase III Study Involving Biosimilar Version of HUMIRA(R)
Alvotech's AVT02 is being developed as a biosimilar of the HUMIRA® high-concentration (100mg/mL) product, expected to be more convenient for patients, compared to biosimilar competitors
400 participants to be enrolled in Phase III study at 30 sites ... Biopharmaceuticals, Generics, Dermatology Alvotech, HUMIRA, biosimilar, plaque psoriasis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 13, 2019 Category: Pharmaceuticals Source Type: news
Why Abbvie May Have A Tough Time Defending Humira's Price Before Congress
Drug maker Abbvie may have to defend the price of its Humira treatment before the U.S. Senate Finance Committee today. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - February 26, 2019 Category: Pharmaceuticals Authors: Bruce Japsen, Contributor Tags: NYSE:ABT NYSE:ABBV NYSE:JNJ NYSE:BMY NYSE:PFE Source Type: news
The world's best-selling drug costs SIX times more in the US than the UK
Drug maker Abbvie made over $18 billion on it's arthritis drug, Humira, in 2017. It has kept a monopoly on the drug by making tiny changes to the formula, which costs over $5,600 in the US. (Source: the Mail online | Health)
Source: the Mail online | Health - February 20, 2019 Category: Consumer Health News Source Type: news
EU Panel Recommends Humira Biosimilars Idacio, Kromeya EU Panel Recommends Humira Biosimilars Idacio, Kromeya
The EMA ' s Committee for Medicinal Products for Human Use has recommended marketing authorization for two biosimilars that are highly similar to Humira (adalimumab, AbbVie).FDA Approvals (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 1, 2019 Category: Consumer Health News Tags: Rheumatology News Alert Source Type: news
Longitudinal TNF Levels Mainly Stable With Adalimumab in RA
FRIDAY, Feb. 1, 2019 -- For patients with rheumatoid arthritis (RA), longitudinal tumor necrosis factor (TNF) concentrations are mainly stable during adalimumab treatment, although early low TNF is strongly linked to nonresponse to treatment,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 1, 2019 Category: Pharmaceuticals Source Type: news
GI Case Quiz: Ileocolonic Anastomosis a Success, New Symptoms Arise
What might cause severe abdominal bloating& diarrhea 3 years after ileocolonic resection and adalimumab/methotrexate treatment? (Source: ConsultantLive)
Source: ConsultantLive - January 30, 2019 Category: Internal Medicine Authors: Ted W. James, MD Tags: Gastrointestinal Disorders Source Type: news
FDA approves J & J ’s Tremfya self-injection pen for psoriasis
FDA has approved Johnson & Johnson’s patient-controlled injector for Tremfya, a treatment for adults with moderate to severe plaque psoriasis.
The self-injection approval may help Tremfya compete with AbbVie’s (NYSE:ABBV) Humira pen, which was previously approved for self-injection by psoriasis patients.
Get the full story on our sister site, Drug Delivery Business.
The post FDA approves J&J’s Tremfya self-injection pen for psoriasis appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - January 30, 2019 Category: Medical Devices Authors: Nancy Crotti Tags: Blog Drug-Device Combinations Food & Drug Administration (FDA) News Well AbbVie Janssen Pharmaceuticals johnsonandjohnson Source Type: news
Drug Companies Greet 2019 With U.S. Price Hikes Drug Companies Greet 2019 With U.S. Price Hikes
Drugmakers kicked off 2019 with price increases in the United States on more than 250 prescription drugs, including the world ' s top-selling medicine, Humira, although the pace of price hikes was slower than last year.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 17, 2019 Category: Consumer Health News Tags: Family Medicine/Primary Care News Source Type: news
